MikroScore
Science-backed ingredient evidence
Weak Evidence Safety: Likely safe Study dose: 1000 mg/day

Acetyl-L-Carnitin

Also known as: ALCAR, Acetyl-L-Carnitine, Acetylcarnitin

Summary Weak Evidence

ALCAR is the brain-accessible form of carnitine popular in cognitive and healthy aging stacks, but evidence is solid rather than remarkable.

EU Health Claims: No approved claims

The EFSA has not approved any health claims for ALCAR regarding cognitive function, aging research, or energy metabolism.

AI Summary

Quick verdict

ALCAR is the brain-accessible form of carnitine popular in cognitive and healthy aging stacks, but evidence is solid rather than remarkable.

What the evidence supports

ALCAR is biologically plausible for neuronal energy metabolism and membrane integrity. Modest evidence exists for benefit in specific neurological contexts and age-related cognitive decline, but the evidence base for healthy aging claims in younger adults is weak.

What is NOT supported

Clinical human trials are absent or very weak. Long-term safety in humans is largely unexplored.

EU/EFSA status

Not approved. The EFSA has not approved any health claims for ALCAR regarding cognitive function, aging researc…

Safety

Likely safe

This AI summary is generated from the structured data on this page.

What is ALCAR?

ALCAR (acetyl-L-carnitine) is the acetylated form of carnitine, valued as the form most accessible to the brain and central nervous system. Unlike regular L-carnitine, which primarily supports muscle mitochondrial energy, ALCAR crosses the blood-brain barrier more efficiently and accumulates in neural tissue.

Mechanism

ALCAR functions in several interrelated ways within neurons:

  • Mitochondrial energy production: In brain mitochondria, ALCAR facilitates the transport of long-chain fatty acids across the inner mitochondrial membrane via carnitine palmitoyltransferase, enabling ATP production from fat oxidation.
  • Acetyl group donation: The acetyl moiety directly supports acetylcholine synthesis via acetyl-CoA. Acetylcholine is central to attention, memory, and cognitive processing.
  • Neuroprotection: ALCAR acts as an antioxidant and anti-apoptotic agent in aging neurons, supporting mitochondrial health under stress.

What do the studies actually show?

The positive case

  • Multiple RCTs in older adults (age 60+) with mild cognitive impairment or age-related cognitive slowing have reported modest improvements in memory, attention, and processing speed over 12–24 weeks at doses of 1.5–3 g/day.
  • In neurological conditions such as mild diabetic neuropathy or age-related neuropathic pain, ALCAR has shown benefit in several controlled trials, with some studies reporting improvements in pain scores and nerve conduction metrics.
  • The mechanistic pathway is sound: ALCAR levels decline with age, and supplementation can partially restore neural mitochondrial function in aging animals and cell cultures.

The limitations

  • Most cognitive studies focus on impaired populations (older adults with mild cognitive impairment or dementia), not healthy younger individuals. Extrapolation to healthy 30–50 year-olds is problematic.
  • Effect sizes are small to moderate; meta-analyses typically report standardized mean differences of 0.3–0.5, corresponding to roughly 5–15% improvements in specific cognitive tests—noticeable but not transformative.
  • Longer-term safety and efficacy data (>6 months) are sparse. Most studies last 12–24 weeks.
  • Many positive studies were conducted in Italy and other European countries; replication in independent U.S. cohorts is limited.

Bottom line: ALCAR has a plausible neuroprotective mechanism and modest evidence in cognitively impaired older adults. For healthy individuals seeking cognitive enhancement, the evidence is much weaker and competitive supplements like alpha-GPC or bacopa have stronger data.

Who might benefit?

  • Older adults (65+) with subjective cognitive decline or mild cognitive impairment: The evidence is most robust here.
  • Individuals with age-related neuropathy: Some evidence for pain relief and nerve function support.
  • Healthy younger individuals: No convincing evidence; expectation should be tempered.

Dosage and timing

  • Standard dose in trials: 1.5–2 g/day, divided into 2–3 doses (e.g., 500–750 mg with meals).
  • Some studies use up to 3 g/day; response appears dose-responsive but diminishing above 2 g/day.
  • Absorption is improved with food; morning and early afternoon doses may be preferred to avoid potential evening stimulation.

Safety profile

ALCAR is well-tolerated in short- and medium-term use (up to 6 months). Side effects in trials are rare and mild:

  • Occasional GI upset, nausea, or headache at higher doses.
  • Very rare: mild insomnia if taken late in the day (due to acetylcholine elevation).
  • No organ toxicity reported in standard dose ranges.
  • Long-term safety (>1 year) has not been rigorously studied.

EFSA regulatory status

  • ALCAR has no approved EFSA health claims for cognitive function, energy, or aging.
  • Marketing claims about “brain energy,” “memory support,” or “healthy aging” are not permitted under EU regulation.

Bottom line

ALCAR is a mid-tier cognitive and neuroprotective agent with a solid mechanistic foundation and modest clinical evidence in specific populations (older adults, neuropathic pain). For healthy younger individuals, it is an interesting experiment rather than an evidence-backed staple. If brain health is the goal, prioritize sleep, cardiovascular fitness, cognitive engagement, and learning—factors with far stronger evidence—before investing heavily in ALCAR.

Key Studies

Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease

Montgomery et al. (2003)

Meta-analytic evidence suggests potential benefit in older and cognitively impaired populations, but findings do not cleanly translate to healthy individuals.

PubMed PMID 12598816

Acetyl-L-Carnitine in the Treatment of Peripheral Neuropathies: A Narrative Review

Fornasari et al. (2026)

Potential benefit in specific neurological contexts, particularly neuropathic conditions, though clinical effect sizes remain modest.

PubMed PMID 41824218

The neurobiology of acetyl-L-carnitine

Traina et al. (2016)

Mechanistically interesting through mitochondrial and antioxidant pathways, but human clinical endpoints remain limited and inconclusive.

PubMed PMID 27100509
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.